Our investigations revealed that common SGLT2 inhibitors used in the treatment of patients with diabetes, CKD, or heart failure modify αKlotho gene expression and Klotho protein secretion in renal MDCK and HK-2 cells. The gene discussed is KL; the disease is chronic kidney disease.